{"component": "definition", "props": {"groups": [{"snippet": "means Illumina Intellectual Property Rights that pertain to or cover aspects or features of the Product (or use thereof) that are common to the Products in all applications and all fields of use. To avoid any doubt, and without limitation, Core IP specifically excludes any and all Intellectual Property Rights relating to NIPT.", "snippet_links": [{"key": "illumina-intellectual-property-rights", "type": "definition", "offset": [6, 43]}, {"key": "the-products", "type": "clause", "offset": [140, 152]}, {"key": "fields-of-use", "type": "clause", "offset": [181, 194]}, {"key": "without-limitation", "type": "clause", "offset": [220, 238]}, {"key": "all-intellectual-property-rights", "type": "clause", "offset": [278, 310]}, {"key": "relating-to", "type": "definition", "offset": [311, 322]}], "samples": [{"hash": "ijPunwRCWEr", "uri": "/contracts/ijPunwRCWEr#core-ip", "label": "Supply, Service, and Support Agreement", "score": 31.3408622742, "published": true}, {"hash": "lcKN7xTO3jI", "uri": "/contracts/lcKN7xTO3jI#core-ip", "label": "Supply, Service, and Support Agreement (Foundation Medicine, Inc.)", "score": 29.7118415833, "published": true}, {"hash": "2Kngbpu6E9c", "uri": "/contracts/2Kngbpu6E9c#core-ip", "label": "Supply, Service, and Support Agreement (Foundation Medicine, Inc.)", "score": 24.6960983276, "published": true}], "size": 7, "hash": "d314caba342384cff6682624c2711b0c", "id": 1}, {"snippet": "means the intellectual property owned or controlled by ABL Group entities, as of the date the Product ships, that pertain to or cover aspects or features of the Product (or use thereof) that are common to the Product in all applications and all fields of use but does not include intellectual property that pertain to or cover aspects or features of the Product (and use thereof) only with regard to specific field(s) or specific application(s).", "snippet_links": [{"key": "the-intellectual-property", "type": "clause", "offset": [6, 31]}, {"key": "owned-or-controlled", "type": "definition", "offset": [32, 51]}, {"key": "group-entities", "type": "definition", "offset": [59, 73]}, {"key": "the-product", "type": "clause", "offset": [90, 101]}, {"key": "fields-of-use", "type": "clause", "offset": [245, 258]}, {"key": "with-regard-to", "type": "clause", "offset": [385, 399]}], "samples": [{"hash": "7eAO8Vd3jQq", "uri": "https://www.abldiagnostics.com/wp-content/uploads/2024/05/20221201_Terms-and-Conditions-of-Sale_CGV_ABL.pdf", "label": "www.abldiagnostics.com", "score": 17.284866333, "published": false}, {"hash": "lJKIm1nMaMA", "uri": "https://www.abldiagnostics.com/wp-content/uploads/2022/09/202209_Terms_Conditions_Sales.pdf", "label": "www.abldiagnostics.com", "score": 15.5702238083, "published": false}, {"hash": "cj7775HK1Wx", "uri": "https://www.abldiagnostics.com/wp-content/uploads/2022/09/202209_Terms_Conditions_Sale_ABL_Group.pdf", "label": "www.abldiagnostics.com", "score": 15.3146266937, "published": false}], "size": 3, "hash": "b498a9caf142728eb06a13e81d496b29", "id": 2}, {"snippet": "means the Business Intellectual Property listed on Schedule 3.", "snippet_links": [{"key": "business-intellectual-property", "type": "clause", "offset": [10, 40]}, {"key": "schedule-3", "type": "clause", "offset": [51, 61]}], "samples": [{"hash": "5V4HPTY2j6u", "uri": "/contracts/5V4HPTY2j6u#core-ip", "label": "Asset Purchase Agreement", "score": 31.3408622742, "published": true}, {"hash": "6RIyvy3KrhB", "uri": "/contracts/6RIyvy3KrhB#core-ip", "label": "Asset Purchase Agreement (Callaway Golf Co)", "score": 23.3189601898, "published": true}, {"hash": "8YKZgwOVKwR", "uri": "https://ir.callawaygolf.com/static-files/c4a1a2bf-66d8-45bc-ae71-a323d5d33c7a", "label": "ir.callawaygolf.com", "score": 10.1704311371, "published": false}], "size": 3, "hash": "dd2e22553eaf1c7974ab9d271ee15763", "id": 3}, {"snippet": "means Intellectual Property required to protect Borrower\u2019s (i) existing somatic hypermutation technology platform as utilized on an on-going basis for antibody development, (ii) antibody product programs actively being pursued as part of the company\u2019s internal or partnered pipeline, including but without limitation the anti-IL-33 and anti-IL-36R antibody programs, and (iii) future acquired or developed Intellectual Property that is material to Borrower\u2019s then-current business.", "snippet_links": [{"key": "technology-platform", "type": "clause", "offset": [94, 113]}, {"key": "product-programs", "type": "clause", "offset": [187, 203]}, {"key": "of-the-company", "type": "clause", "offset": [235, 249]}, {"key": "without-limitation", "type": "clause", "offset": [298, 316]}, {"key": "developed-intellectual-property", "type": "clause", "offset": [396, 427]}, {"key": "to-borrower", "type": "definition", "offset": [445, 456]}, {"key": "current-business", "type": "definition", "offset": [464, 480]}], "samples": [{"hash": "4FMBRWt9l0t", "uri": "/contracts/4FMBRWt9l0t#core-ip", "label": "Loan and Security Agreement (Anaptysbio Inc)", "score": 28.0444908142, "published": true}, {"hash": "dcGMLT7oIL5", "uri": "/contracts/dcGMLT7oIL5#core-ip", "label": "Loan and Security Agreement (Anaptysbio Inc)", "score": 27.1245727539, "published": true}, {"hash": "88p6tCXtFpo", "uri": "/contracts/88p6tCXtFpo#core-ip", "label": "Loan and Security Agreement (Anaptysbio Inc)", "score": 26.5386714935, "published": true}], "size": 3, "hash": "08a2f28e717ca314015c5bc2033ec70f", "id": 4}, {"snippet": "is defined in Section 8.15. \"CROSS-LICENSE AGREEMENT\" means the Cross-License and OEM Agreement signed by the parties on October 5, 1998 attached hereto as Exhibit 4.14B executed and delivered by Seagate Software Information Management Group, Inc., Newco and VERITAS simultaneously with this Agreement. \"DISPOSAL,\" \"RELEASE,\" and \"THREATENED RELEASE\" shall have the definitions assigned thereto by the Comprehensive Environmental Response, Compensation and Liability Act of 1980, 42 U.S.C. sec. 9601 et seq., as amended (\"CERCLA\"). \"DELAWARE LAW\" means the Delaware General Corporation Law, as in effect from time to time. \"DEVELOPMENT AGREEMENT\" means the Development and License Agreement signed by the parties on October 5, 1998 attached hereto as Exhibit 4.14A executed and delivered by Newco, VERITAS and STI simultaneously with this Agreement. \"DLJ\" means Dona\u2587\u2587\u2587\u2587\u2587, \u2587\u2587fk\u2587\u2587 & \u2587enr\u2587\u2587\u2587\u2587 \u2587\u2587\u2587urities Corporation. \"DOLLARS\" or \"$\" means U.S. dollars. \"EFFECTIVE TIME\" shall mean the effective time and date that the Certificate of Merger is deemed filed with the Secretary of State of the State of Delaware in accordance with the relevant provisions of the Delaware Law. \"EMPLOYEE\" and \"EMPLOYEES\" has the meaning specified in Section 12.1(a). \"EMPLOYEE BENEFIT PLAN\" is defined in Section 2.8(a). \"ENCUMBRANCE\" means any pledge, lien, collateral assignment, security interest, mortgage, deed of trust, title retention, conditional sale or other security arrangement, or any charge, adverse claim of title, ownership or use, or any other encumbrance of any kind. \"ENVIRONMENTAL DAMAGE\" means any actual or alleged Liability (including without limitation Liability for investigatory costs, cleanup costs, governmental response costs, natural resources damages, property damages, personal injuries or penalties) arising A-82 84 out of, based on or relating to (i) the presence, discharge, emission or release into the environment of any Hazardous Substance or (ii) facts or circumstances forming the basis of any violation, or alleged violation, of any Environmental Law. \"ENVIRONMENTAL LAWS\" means all federal, state, local and international laws and regulations relating to pollution, the protection of human health or the environment (including without limitation ambient air, surface water, ground water, land surface or subsurface strata), including without limitation laws and regulations relating to emissions, discharges, releases or threatened releases of Hazardous Substances, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Substances. \"ERISA\" means the Employee Retirement Income Security Act of 1974, as amended, and the rulings and regulations promulgated thereunder. \"EXCHANGE ACT\" is the Security Exchange Act of 1934, as amended. \"EXCLUDED LIABILITIES\" shall have the meaning defined for it in Section 1.4(b)(ii). \"FINAL DATE\" is defined in the last paragraph of Section 9.1. \"FINAL LIST\" is defined in Section 12.1(a). \"FINANCIAL ASSETS\" shall mean (i) all cash and cash equivalents of any of the Contributed Companies, Contributed Subsidiaries or Contributing Companies arising from or generated by the Group Business; (ii) any of the Contributed Companies or Contributed Subsidiaries and other Group Business accounts receivable, unbilled receivables, and other amounts receivable from or to third parties; (iii) all rights of any of the Contributed Companies or Contributed Subsidiaries of every nature and description under or arising out of all insurance policies of any of the Contributed Companies or Contributed Subsidiaries;", "snippet_links": [{"key": "defined-in-section", "type": "clause", "offset": [3, 21]}, {"key": "signed-by-the-parties", "type": "clause", "offset": [96, 117]}, {"key": "attached-hereto-as-exhibit", "type": "definition", "offset": [137, 163]}, {"key": "executed-and-delivered", "type": "clause", "offset": [170, 192]}, {"key": "management-group", "type": "definition", "offset": [225, 241]}, {"key": "simultaneously-with", "type": "clause", "offset": [267, 286]}, {"key": "this-agreement", "type": "clause", "offset": [287, 301]}, {"key": "threatened-release", "type": "definition", "offset": [331, 349]}, {"key": "the-definitions", "type": "definition", "offset": [362, 377]}, {"key": "environmental-response", "type": "clause", "offset": [416, 438]}, {"key": "act-of-1980", "type": "definition", "offset": [467, 478]}, {"key": "as-amended", "type": "definition", "offset": [509, 519]}, {"key": "delaware-law", "type": "clause", "offset": [533, 545]}, {"key": "delaware-general-corporation-law", "type": "definition", "offset": [557, 589]}, {"key": "in-effect", "type": "clause", "offset": [594, 603]}, {"key": "from-time-to-time", "type": "clause", "offset": [604, 621]}, {"key": "development-agreement", "type": "definition", "offset": [624, 645]}, {"key": "development-and-license-agreement", "type": "definition", "offset": [657, 690]}, {"key": "by-newco", "type": "clause", "offset": [788, 796]}, {"key": "effective-time-and-date", "type": "clause", "offset": [984, 1007]}, {"key": "certificate-of-merger", "type": "clause", "offset": [1017, 1038]}, {"key": "secretary-of-state-of-the-state-of-delaware", "type": "clause", "offset": [1064, 1107]}, {"key": "in-accordance-with", "type": "definition", "offset": [1108, 1126]}, {"key": "provisions-of-the", "type": "clause", "offset": [1140, 1157]}, {"key": "employee-benefit-plan", "type": "definition", "offset": [1246, 1267]}, {"key": "collateral-assignment", "type": "definition", "offset": [1337, 1358]}, {"key": "security-interest", "type": "definition", "offset": [1360, 1377]}, {"key": "deed-of-trust", "type": "definition", "offset": [1389, 1402]}, {"key": "title-retention", "type": "clause", "offset": [1404, 1419]}, {"key": "conditional-sale", "type": "clause", "offset": [1421, 1437]}, {"key": "security-arrangement", "type": "definition", "offset": [1447, 1467]}, {"key": "claim-of-title", "type": "clause", "offset": [1492, 1506]}, {"key": "ownership-or-use", "type": "clause", "offset": [1508, 1524]}, {"key": "environmental-damage", "type": "clause", "offset": [1565, 1585]}, {"key": "liability-for", "type": "clause", "offset": [1655, 1668]}, {"key": "cleanup-costs", "type": "definition", "offset": [1690, 1703]}, {"key": "response-costs", "type": "clause", "offset": [1718, 1732]}, {"key": "natural-resources-damages", "type": "definition", "offset": [1734, 1759]}, {"key": "property-damages", "type": "clause", "offset": [1761, 1777]}, {"key": "personal-injuries", "type": "clause", "offset": [1779, 1796]}, {"key": "based-on", "type": "definition", "offset": [1835, 1843]}, {"key": "relating-to", "type": "definition", "offset": [1847, 1858]}, {"key": "the-environment", "type": "clause", "offset": [1913, 1928]}, {"key": "basis-of", "type": "clause", "offset": [1999, 2007]}, {"key": "alleged-violation", "type": "clause", "offset": [2026, 2043]}, {"key": "environmental-laws", "type": "definition", "offset": [2072, 2090]}, {"key": "laws-and-regulations", "type": "clause", "offset": [2142, 2162]}, {"key": "protection-of", "type": "definition", "offset": [2190, 2203]}, {"key": "human-health", "type": "clause", "offset": [2204, 2216]}, {"key": "ambient-air", "type": "definition", "offset": [2266, 2277]}, {"key": "surface-water", "type": "clause", "offset": [2279, 2292]}, {"key": "ground-water", "type": "definition", "offset": [2294, 2306]}, {"key": "releases-of-hazardous-substances", "type": "clause", "offset": [2452, 2484]}, {"key": "handling-of-hazardous-substances", "type": "clause", "offset": [2602, 2634]}, {"key": "employee-retirement-income-security-act-of-1974", "type": "definition", "offset": [2654, 2701]}, {"key": "exchange-act-of-1934", "type": "definition", "offset": [2802, 2822]}, {"key": "excluded-liabilities", "type": "definition", "offset": [2837, 2857]}, {"key": "final-date", "type": "definition", "offset": [2921, 2931]}, {"key": "section-91", "type": "clause", "offset": [2969, 2980]}, {"key": "final-list", "type": "definition", "offset": [2983, 2993]}, {"key": "financial-assets", "type": "clause", "offset": [3027, 3043]}, {"key": "cash-and-cash-equivalents", "type": "definition", "offset": [3064, 3089]}, {"key": "contributed-companies", "type": "definition", "offset": [3104, 3125]}, {"key": "contributed-subsidiaries", "type": "definition", "offset": [3127, 3151]}, {"key": "contributing-companies", "type": "definition", "offset": [3155, 3177]}, {"key": "group-business", "type": "definition", "offset": [3211, 3225]}, {"key": "other-group", "type": "definition", "offset": [3297, 3308]}, {"key": "business-accounts-receivable", "type": "definition", "offset": [3309, 3337]}, {"key": "unbilled-receivables", "type": "definition", "offset": [3339, 3359]}, {"key": "amounts-receivable", "type": "clause", "offset": [3371, 3389]}, {"key": "to-third-parties", "type": "clause", "offset": [3398, 3414]}, {"key": "rights-of", "type": "definition", "offset": [3426, 3435]}, {"key": "and-description", "type": "clause", "offset": [3513, 3528]}, {"key": "arising-out-of", "type": "definition", "offset": [3538, 3552]}, {"key": "policies-of", "type": "definition", "offset": [3567, 3578]}], "samples": [{"hash": "jTASvuWRt0g", "uri": "/contracts/jTASvuWRt0g#core-ip", "label": "Agreement and Plan of Reorganization (Seagate Software Inc)", "score": 18.0, "published": true}, {"hash": "8KKDx5zFGHk", "uri": "/contracts/8KKDx5zFGHk#core-ip", "label": "Agreement and Plan of Reorganization (Seagate Software Inc)", "score": 18.0, "published": true}], "size": 2, "hash": "bafa10fcad9a052806753b8cc4ceecd7", "id": 5}, {"snippet": "means Illumina Intellectual Property Rights that pertain to or cover aspects or features of any Supplied Product (or use thereof), or software embedded in or installed on Illumina hardware (or use thereof), or software that Illumina hardware is designed to communicate or interact with (or use thereof), that are common to such Supplied Product in all applications and all fields of use. To avoid any doubt, and without limitation, Core IP specifically excludes any and all Intellectual Property Rights relating to NIPT.", "snippet_links": [{"key": "illumina-intellectual-property-rights", "type": "definition", "offset": [6, 43]}, {"key": "supplied-product", "type": "definition", "offset": [96, 112]}, {"key": "illumina-hardware", "type": "definition", "offset": [171, 188]}, {"key": "fields-of-use", "type": "clause", "offset": [373, 386]}, {"key": "without-limitation", "type": "clause", "offset": [412, 430]}, {"key": "all-intellectual-property-rights", "type": "clause", "offset": [470, 502]}, {"key": "relating-to", "type": "definition", "offset": [503, 514]}], "samples": [{"hash": "7hbVbDvcNEc", "uri": "https://www.sec.gov/Archives/edgar/data/2019410/000110465925052381/tm2415719d15_ex10-2a.htm", "label": "Caris Life Sciences, Inc.", "score": 20.38945961, "published": false}, {"hash": "lknmcnKCdQz", "uri": "https://www.illumina.com/content/dam/illumina-marketing/documents/applications/cancer/illumina-open-offer.pdf", "label": "www.illumina.com", "score": 9.3572893143, "published": false}], "size": 2, "hash": "9c31021e83608c5600ac5016a315d018", "id": 6}, {"snippet": "means Illumina Intellectual Property Rights that pertain to or cover aspects or features of the Product (or use thereof) that are common to the Products in all applications and all fields of use. To avoid any doubt, and without limitation, Core IP specifically excludes any and all Intellectual Property Rights relating to [\u2026***\u2026].", "snippet_links": [{"key": "illumina-intellectual-property-rights", "type": "definition", "offset": [6, 43]}, {"key": "the-products", "type": "clause", "offset": [140, 152]}, {"key": "fields-of-use", "type": "clause", "offset": [181, 194]}, {"key": "without-limitation", "type": "clause", "offset": [220, 238]}, {"key": "all-intellectual-property-rights", "type": "clause", "offset": [278, 310]}, {"key": "relating-to", "type": "definition", "offset": [311, 322]}], "samples": [{"hash": "5nbhVQT1r92", "uri": "/contracts/5nbhVQT1r92#core-ip", "label": "Supply, Service, and Support Agreement (Foundation Medicine, Inc.)", "score": 29.6023273468, "published": true}, {"hash": "fznVhZhtV0G", "uri": "http://pdf.secdatabase.com/221/0001564590-18-021082.pdf", "label": "pdf.secdatabase.com", "score": 18.5167695775, "published": false}], "size": 2, "hash": "d7e621e5e5eb214d70634463aaaf35c3", "id": 7}, {"snippet": "means the Intellectual Property Rights summary details of which are set out in Appendix 3.9(a)(2) of the Company Disclosure Letter and all other Intellectual Property Rights material to the business of the Company Entities.", "snippet_links": [{"key": "the-intellectual-property-rights", "type": "clause", "offset": [6, 38]}, {"key": "details-of", "type": "clause", "offset": [47, 57]}, {"key": "set-out", "type": "definition", "offset": [68, 75]}, {"key": "company-disclosure-letter", "type": "definition", "offset": [105, 130]}, {"key": "other-intellectual-property-rights", "type": "definition", "offset": [139, 173]}, {"key": "company-entities", "type": "definition", "offset": [206, 222]}], "samples": [{"hash": "i05t0cDuTBd", "uri": "/contracts/i05t0cDuTBd#core-ip", "label": "Business Combination Agreement", "score": 34.966053009, "published": true}, {"hash": "SGNmoN78Gv", "uri": "/contracts/SGNmoN78Gv#core-ip", "label": "Business Combination Agreement (Angel Pond Holdings Corp)", "score": 33.0848731995, "published": true}], "size": 2, "hash": "6a0dbf8921b9ba1563edf3a73c08e4a4", "id": 8}, {"snippet": "means any and all BioNano Intellectual Property Rights to the extent pertaining to or covering aspects or features of the BioNano Components(or use thereof), IVD Kits and IVD Instrument (or use thereof) without regard to (i.e., not particular to) any specific field(s) of use or specific application(s). For clarity, Core IP includes BioNano Patents, but excludes any trademark, service \u2587\u2587\u2587\u2587, trade dress, brand names, marks, or logos.", "snippet_links": [{"key": "intellectual-property-rights", "type": "clause", "offset": [26, 54]}, {"key": "to-the-extent", "type": "clause", "offset": [55, 68]}, {"key": "pertaining-to", "type": "definition", "offset": [69, 82]}, {"key": "ivd-instrument", "type": "definition", "offset": [171, 185]}, {"key": "for-clarity", "type": "clause", "offset": [304, 315]}, {"key": "trade-dress", "type": "clause", "offset": [393, 404]}, {"key": "brand-names", "type": "definition", "offset": [406, 417]}], "samples": [{"hash": "gO4pPuMuCTB", "uri": "/contracts/gO4pPuMuCTB#core-ip", "label": "Manufacturing Agreement (BioNano Genomics, Inc)", "score": 29.4873371124, "published": true}, {"hash": "39w5D5ldfeE", "uri": "/contracts/39w5D5ldfeE#core-ip", "label": "Manufacturing Agreement (BioNano Genomics, Inc)", "score": 29.3641338348, "published": true}], "size": 2, "hash": "49cdcd3d5ff07248b196c65c6ecddc7c", "id": 9}, {"snippet": "means [****].", "snippet_links": [], "samples": [{"hash": "35wLTiPNn97", "uri": "/contracts/35wLTiPNn97#core-ip", "label": "Loan and Security Agreement (Stemcells Inc)", "score": 24.7754955292, "published": true}, {"hash": "ldXO47McnHh", "uri": "/contracts/ldXO47McnHh#core-ip", "label": "Loan and Security Agreement (Stemcells Inc)", "score": 24.3237514496, "published": true}], "size": 2, "hash": "1e83f8111f883b0fd2a42bcdc6f1004f", "id": 10}], "next_curs": "ClQSTmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjALEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIQY29yZS1pcCMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"snippet": "means Illumina Intellectual Property Rights that pertain to or cover aspects or features of the Product (or use thereof) that are common to the Products in all applications and all fields of use. To avoid any doubt, and without limitation, Core IP specifically excludes any and all Intellectual Property Rights relating to NIPT.", "title": "Core IP", "size": 40, "id": "core-ip", "examples": ["Except as expressly stated in this Section 3(a) with respect to <strong>Core IP</strong>, no right or license under any Illumina Intellectual Property Rights is or are granted, expressly, by implication, or by estoppel, to Customer under this Agreement.", "In addition, the Contributing Companies shall have taken such steps in causing the registration of copyrights in the <strong>Core IP</strong> and the recordation of any previous assignments in the chain of title for the <strong>Core IP</strong> which are necessary to enable Newco to record the <strong>Core IP</strong> assignments.", "Except as expressly stated in this Section with respect to <strong>Core IP</strong>, no right or license under any Illumina Intellectual Property Rights is or are granted, expressly, by implication, or by estoppel, to Customer under this Agreement.", "In no event may Artiva credit payments under a Third Party License to reduce the Product Royalties with respect to a Product under this Section 3.2(e)(ii) and also to reduce the <strong>Core IP</strong> Royalties payable with respect to the same Product that is a Licensed Product under the Option Agreement.", "Without limiting the generality of the foregoing, Confidential Information will include, without limitation, the (i) Ace-Up <strong>Core IP</strong>, (ii) Client confidential or proprietary information made known to Coach, such as personal or business information from or about Client or its employees, (iii) this Agreement, including any associated fees and payments, and (iv) Ace-Up\u2019s business and offerings, including methodologies, pricing, discounts, client lists, and other information.", "This Agreement shall become effective on the Effective Date and, unless earlier terminated pursuant to this Article 10, shall remain in effect until the expiration of the last <strong>Core IP</strong> Royalty Term in the Territory (the \u201cTerm\u201d).", "In no event will the <strong>Core IP</strong> Royalties be reduced for any reason whatsoever other than as provided in this Section 6.1(e).", "For Licensed Products sold by Artiva or its Affiliates after the effective date of a termination, Artiva shall continue to pay <strong>Core IP</strong> Royalties pursuant to Section 6.1, as applicable.", "Following expiration of the <strong>Core IP</strong> Royalty Term for any Licensed Product in a given country, no further <strong>Core IP</strong> Royalties shall be payable in respect of GCLC Core Technology for such Licensed Product in such country, and the Core License granted to Artiva under Section 2.1 with respect to such Licensed Product in such country shall automatically become fully paid-up, perpetual and royalty-free and shall survive any expiration or termination of this Agreement.", "The total deductions under Sections 6.1(e)(ii) and (iii) shall not reduce the <strong>Core IP</strong> Royalties payable to GCLC under Section 6.1 (as reduced under Section 6.1(e)(i), if applicable) with respect to a Licensed Product in a given country in any calendar quarter by more than [***]."], "related": [["foreground-ip", "Foreground IP", "Foreground IP"], ["developed-ip", "Developed IP", "Developed IP"], ["foreground-ipr", "Foreground IPR", "Foreground IPR"], ["collaboration-ip", "Collaboration IP", "Collaboration IP"], ["background-ip", "Background IP", "Background IP"]], "related_snippets": [], "updated": "2025-07-10T04:27:38+00:00"}, "json": true, "cursor": ""}}